Laxmi Organic Q1FY27: consolidated PAT +217% YoY as OPM more than doubles to 11.8%
PAT +216.55% YoY · revenue +39.75% · margins expanding
₹968.34 Cr
+39.75% YoY
₹67.72 Cr
+216.55% YoY
6.97%
+3.9pp YoY
₹2.44
Laxmi Organic Industries' consolidated Q1 FY27 (quarter ended June 30, 2026) results, approved by the board on July 29, 2026, show revenue from operations of ₹968.34 Cr, up 39.7% YoY from ₹692.93 Cr and 31.7% QoQ from ₹735.31 Cr. Consolidated PAT came in at ₹67.72 Cr, up 216.6% YoY from ₹21.39 Cr and 214.2% QoQ from ₹21.55 Cr, with EPS of ₹2.44 against ₹0.77 in both the year-ago and preceding quarters. Standalone tells the same story — PAT of ₹63.30 Cr versus ₹22.97 Cr a year ago — so there is no material divergence between the two bases this quarter.
Q1 FY-2027 vs prior quarters
The improvement is margin-led rather than a one-off: operating margin (OPM) more than doubled to 11.81% from 4.44% a year ago and 7.29% last quarter, while net margin widened to 6.99% from 3.06% YoY. Neither statement carries an exceptional item this quarter or in the comparison periods, so the growth is organic. Notably, PBT itself rose even faster — 546.6% YoY to ₹91.76 Cr from ₹14.19 Cr — than PAT's 216.6%, because the year-ago quarter benefited from an unusual net tax credit of ₹7.20 Cr tied to a tax-regime reassessment (Note 5), versus a normal ₹24.04 Cr tax charge this quarter under the new 25.17% regime rate. The headline 217% PAT growth therefore understates the scale of the underlying operating turnaround, since last year's comparison PAT was itself flattered by that credit.
The stock went into the print at ₹200.51, up 29.4% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.
Management indicated sequential revenue growth of 9% in Q4 FY26 driven by both Essentials and Specialties businesses, with margin improvements. While FY26 saw a 6% degrowth year-on-year due to margin pressures and deflationary feedstocks, the company anticipates a good start to FY27. New capacities, particularly the Da
— This quarter: beat
Laxmi gave no formal quantitative revenue or margin target for FY27 on its Q4 FY26 call, citing market volatility, but did flag a "good start to FY27" and cautious optimism — this print, with revenue up 31.7% sequentially against a prior guided cadence of ~9% and a near-tripling of OPM, comfortably clears that qualitative bar. A web search turned up no specific analyst consensus estimate for this quarter's PAT or revenue, so the print's standing versus Street is marked unknown rather than guessed. No separate management press release was available for this filing to cross-check against the numbers. The quarter's other corporate developments — the FY26 annual report/BRSR filing and the AGM set for August 5, 2026 — are administrative and don't bear on the operating print.
W1
Dahej Phase 2 capacity contribution guided to begin in H2 FY27 — watch for incremental revenue/margin uplift when it lands
W2
Hitachi project ramp guided for Q3 FY27
W3
Whether the 11.81% OPM print holds versus the 4.44%-7.29% range seen over the last two quarters, given management has given no explicit FY27 margin target
Record pricing gains mask commodity dependence; Q2 headwinds loom
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met prior 'good start to FY27' guidance via pricing tailwind. Dahej Phase 1 on track; no numeric FY27 target set or missed. Specialty deferred. No cuts to prior guidance, but no new targets either.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered exceptional 40% YoY revenue growth and 217% PAT growth on commodity spreads (acetic acid +200% in March). However, 75% of growth is price-realization, not organic volume or structural gains. Essentials EBITDA of 11–12% management signals is an upside outlier; cycle average is mid-single-digit. Working capital surged via precautionary stocking, flagging liquidity pressure. Key risk: Q2 explicitly hedged by management ('too early to say') due to West Asia 2.0 crisis and China typhoon.
₹968.3 Cr
Revenue · +39.7% YoY₹67.7 Cr
Reported PAT · +216.6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Strong broad-based performance, 40% YoY revenue growth
METDelivered 39.7% YoY, 31.7% QoQ. Essentials +50%, Specialty +17%. Price-driven, not organic volume.
Enterprise volume growth ~10%, rest price and mix
METIf 40% total and 10% volume, 30% is price/mix. Consistent with the split.
Essentials EBITDA 11–12% this quarter, mid-single-digit over cycle
MISSQ1 OPM 11.8%. Management cautions this is upside outlier; cycle average mid-single-digit, vs Q3 FY26 low single-digit.
Net working capital increased; will normalize over time
METAcknowledged. Tied to precautionary raw material stocking amid volatility. Cash headwind until normalization.
Dahej Phase 2 85% capex capitalized in Q2, ramp Q4 FY27
METTimeline confirmed. Customer qualification Q3, ramp Q4. No FY28 revenue quantum disclosed.
Specialty aspires 20–25% margin range, multi-year journey
PartialSpecialty +17% YoY vs Essentials +50%; weaker momentum. 20–25% deferred post-ramp; 'might not be there short term'.
Earnings quality
What changed since the last call
Q1 result vs prior expectation
UpgradePrior call expected 'good start to FY27'. Q1 delivered 39.7% YoY revenue, 216.6% PAT growth, well above baseline. Upgrade driven by commodity tailwind (acetic acid 200% spike, ethyl acetate spreads above 12-year average), not structural.
Essentials margin outlook
NeutralNo numeric FY27 margin target set or revised. Management reaffirmed mid-single-digit cyclic target; Q1 11–12% flagged as upside outlier, not new normal.
FY27 forward guidance
WithdrawnNo full-year FY27 revenue or margin target provided. Management withheld ('bear with us'), citing forward uncertainty. Deferred to later call for FY28 guidance.
Q2 outlook tone
DowngradeManagement explicitly cautious on Q2 ('too early to say') due to West Asia 2.0 crisis, South China typhoon disruptions. Leading indicators show continued volatility in acetic acid, methanol.
The Q&A
Analysts pressed hard on margin sustainability (Vansh: 'Is 12% sustainable for 1–2 years?'), capex ROE assumptions (Giriraj: Did project economics hold?), and forward guidance (multiple: FY28 Dahej/Hitachi contribution quantum). Management transparent on cyclicality and challenges but deferred quantified guidance, indicating limited visibility on forward run-rate. No evasion per se, but significant information gaps.
Dahej capex and FY28 impact — Giriraj Daga, Visaria Family Trust
PartialFull-year capex ₹125–150 Cr. Phase 2 85% capex capitalizes in Q2. FY28 revenue/EBITDA guidance deferred. Ramp Q4 FY27, then Q3/FY29 focus. Doubling diketene capability; strategy to penetrate segments.
Margin sustainability medium-term — Vansh, RoboCapital
PartialNo straight answer. Essentials cyclic; need over-the-cycle view. Q3 FY26 pressure, now Q1 upside. Important: right to operate (scale, integration, upcycle benefits). Specialty also recovering post-FY26 feedstock deflation.
Volume vs price split 40% growth — Vansh, RoboCapital
AnsweredEnterprise: 10% volume growth, rest from price and product mix. Multiple products; hard to pin down precisely.
Essentials demand rest of FY27 — Abu Rafa, Wealth Catalyst
PartialEssentials cyclic, steered with agility. End-to-end, customer relationships strong. Too premature for specifics. 11–12% EBITDA gives us right to expand.
Acetic anhydride pharma demand — Abu Rafa, Wealth Catalyst
AnsweredCOVID paracetamol surge increased anhydride demand; now muted. But seeing positive momentum currently.
Essentials volume growth and ramp timeline — Hetvi, HS Investments
DodgedWorld-scale ethyl acetate capacity at Lote now online. Dahej Phase 1 at good utilization, ramping with customer. Phase 2 taking shape. Laxmi has track record of ramping, not running idle. Numbers shared as conversation progresses.
Hitachi project status and FY28 contribution — Rohit, 360 ONE Capital
AnsweredProject Vaayu on track. Mechanical completion early Q3. Ramp-up with partner thereafter. FY28 capacity available; scale-up expected.
Electrochemical fluorination partnerships — Rohit, 360 ONE Capital
DodgedStill leader in electrochemical fluorination. Robust specialty pipeline leveraging technology. Partnerships TBA in due course. Stay tuned.
Specialty margin profile and sustainability — Manav Mehta, Mehta Investment
PartialFY26 impacted by phaseout of 10% revenue product and deflationary feedstock pricing (−25%). Site 2 was fully utilized pre-Dahej; bottom-sliced portfolio. Dahej Phase 2 now opens constrained products. Specialty batch/seasonal/campaign; need 2–3 year view. Aspire 20–25% historically; might not be short term due to ramp.
Post-capex depreciation and debt repayment — Manav Mehta, Mehta Investment
AnsweredDepreciation increases from Q2 when Phase 2 capitalizes. Tentative ₹7–7.5 Cr incremental/quarter. Debt repayment starts next year, continues 5 years.
Guidance
FY27 full-year guidance: Not provided; deferred
LowQ1 delivered 39.7% YoY, but management withheld FY27 annual target. Flagged Q2 volatility.
Dahej Phase 2 ramp Q4 FY27, scale-up FY28
MediumMechanical completion Q2, qualification Q3, ramp Q4. No FY28 revenue quantum disclosed.
Hitachi (Project Vaayu) FY28 revenue begin
MediumMechanical completion early Q3. Ramp-up FY28+. No specific revenue or timeline for material contribution.
Essentials: mid-single-digit EBITDA over the cycle
MediumQ1 11–12% flagged as upside outlier. Q3 FY26 low single-digit. Cyclic; mid-single-digit normalized target.
Specialty: aspire 20–25% margin historically, ramp-dependent
LowCurrently ramping. Management: 'might not be there short term'. Deferred to post-ramp visibility.
FY27 capex ₹125–150 Cr (all capex incl. Dahej)
HighDahej Phase 2 85% capitalization Q2. Incremental depreciation ₹7–7.5 Cr/quarter from Q2 onwards.
Risks the call surfaced
Commodity price volatility
HighAcetic acid, methanol, ethyl acetate spiked 200%+ in March. Q1 benefited from high spreads (ethyl acetate above 12-year average of $215–220). Normalization/deflation will compress margins sharply, especially Essentials.
Geopolitical supply chain disruption
MediumWest Asia 2.0 crisis, Gulf of Hormuz, Red Sea tensions, South China typhoon creating vessel scarcity and transportation bottlenecks. Q2 explicitly flagged by management as volatile.
Working capital deterioration
MediumNet working capital increased Q1 due to precautionary raw material stocking. If inventory doesn't convert or receivables stretch, material cash impact.
Essentials margin cyclicality
MediumEssentials EBITDA swings from low single-digit (Q3 FY26) to 11–12% (Q1 FY27). Cyclic; Q1 is upside outlier. Reversion to mid-single-digit normalized target will disappoint consensus.
Specialty margin recovery uncertainty
MediumSpecialty +17% YoY vs Essentials +50%, indicating weaker growth. FY26 impacted by product phaseout (10% revenue) and feedstock deflation. Management aspires 20–25% but cautions 'might not be short term'. Timeline unclear.
Management
Score 6/10. Transparent on challenges (West Asia, typhoon volatility, cyclicality). Candid on Essentials being steered over cycle, not quarter-to-quarter. Deferred FY27/FY28 quantified guidance ('bear with us'). Some opacity on specialty forward numbers and capacity ramp timeline. Strong track record ramping capacity, securing long-term customer contracts, navigating commodity cycles. Dahej Phase 1 on track, Site 1 turnaround executed safely. Hitachi and Dahej Phase 2 ramp timelines not yet proven (still execution).
1 · Q2 FY27
Dahej Phase 2 (85% capex) capitalized; working capital normalization watch
2 · Q3 FY27
Dahej Phase 2 customer qualification; Hitachi mechanical completion expected
3 · Q4 FY27
Dahej Phase 2 ramp-up begins; fluorination contribution upside if monsoons favorable
Key risk: Q2 explicitly hedged by management ('too early to say') due to West Asia 2.0 crisis and China typhoon.
Record Growth Veils a Pricing Cycle, Not Organic Gain
Laxmi delivered 40% revenue growth and 217% PAT growth, but 75% was pricing-driven from commodity spikes. Management cautions margins are cyclic outliers and withheld FY27 guidance, signaling uncertainty ahead.
₹968.3 Cr
+39.7% YoY | +31.7% QoQ
₹67.7 Cr
+216.6% YoY | +214.2% QoQ
11.8%
Essentials 11–12% (flagged as cyclic)
~10%
Rest from pricing/mix
On the headline, Laxmi just posted its strongest quarter in recent memory — 40% revenue growth, 217% PAT growth. But dig into the call, and management tells a different story: 75% of that growth is pricing and product mix, not volume. Essentials margins of 11–12%, while reporting-card stellar, are flagged as 'cyclic upside' against a mid-single-digit normalized target. And management deferred all forward guidance, signaling caution heading into Q2.
Where the growth really came from
Within that, Essentials surged +50% YoY (mix of double-digit volume plus strong pricing), while Specialty lagged at +17% — a red flag for underlying momentum. The company had just commissioned world-scale ethyl acetate capacity at Lote and was ramping a new diketene customer contract, but the headline growth was driven by commodities, not structural gains.
The margin that management doesn't want you to bank on
Essentials business is a business to be viewed over the cycle. We were at low single-digit EBITDA, now high double-digit 11–12%. We expect over cycle, mid-range single-digit fair estimation.
That's the sentence that does the heavy lifting. Q1's 11.8% operating margin and Essentials EBITDA of 11–12% look stellar on paper. Management just said: don't get attached. Three quarters ago (Q3 FY26), Essentials was in low single-digits. Now it's at the high end. Over the cycle, they expect mid-single-digits. The 11–12% is an upside outlier from commodity tailwinds, not a new baseline.
What management is actually saying vs. what holds up
Strong broad-based 40% YoY revenue growth
Delivered 39.7% YoY. Essentials +50%, Specialty +17%. But ~10% is volume; ~30% is pricing/mix from acetic acid +200%, ethyl acetate at 12-year highs.
Supported with caveat
Essentials EBITDA 11–12% this quarter
Confirmed. Q1 OPM 11.8%, Essentials margin flagged as cyclic upside. Q3 FY26 was low single-digit. Management targets mid-single-digit over cycle.
Contradicted (cyclical, not baseline)
Working capital increased but will normalize
Acknowledged. Tied to precautionary raw material stocking in volatile West Asia environment. Cash headwind until normalization.
Supported
Dahej Phase 2 capex 85% to capitalize in Q2, ramp Q4 FY27
Timeline confirmed. Capex ₹125–150 Cr full-year. Phase 2 capex capitalizes Q2, customer qualification Q3, ramp Q4 FY27.
Supported
Specialty aspires 20–25% margin range
Historically yes. Currently ramping. Management: 'might not be there short term' post-Dahej capex. Deferred to later visibility.
Partial (deferred)
Hitachi mechanical completion early Q3 FY27
Mechanical completion early Q3 confirmed. Ramp-up FY28+. No specific revenue or EBITDA quantum for FY27/FY28 disclosed.
Answered (timing) but incomplete (impact)
What changed on this call
No FY27 annual guidance. Prior quarters, management set revenue/margin targets. This time, none. Asked repeatedly for FY27 run-rate margins or Dahej/Hitachi FY28 contribution, management deferred: 'bear with us.' The message: limited forward visibility, waiting for Q2 to clarify. Q2 explicitly hedged. West Asia 2.0 crisis, South China typhoon, vessel scarcity, freight cost spikes. Management cautioned 'too early to say' on Q2 performance. Not pessimistic, but guarded.
Capex execution on track. Dahej Phase 1 at good utilization with customer ramp. Phase 2 (60% diketene capacity) 85% capex to capitalize Q2. Hitachi mechanical completion Q3. Incremental depreciation ₹7–7.5 Cr/quarter from Q2 onwards. No delays flagged; management confident on execution.
How the market read the print
Laxmi announced results on Jul 29, 2026, after the market close at ₹200.51. The stock fell 9.15% on day 1 and held to around −10% by day 3. That move reflects the fundamental tension: yes, growth is real; no, it's not sustainable. The market had priced in the 'good start to FY27' narrative. The result confirmed growth, but management's refusal to raise full-year guidance and explicit caution on Q2 told the street that the company doesn't believe the upside is structural.
Institutionally, FII ownership ticked down 45 bps quarter-on-quarter (1.15% current vs. 1.60% prior), a modest trim but directionally telling — institutions are not adding on commodity tailwinds. The stock is 13.66% below its all-time high of ₹209 but up 67.71% from its 52-week low. The drawdown is not a capitulation; it's selective trimming of over-positioning.
40% revenue growth and 217% PAT in absolute terms
World-scale ethyl acetate capacity commissioned; diketene customer ramp on track
Dahej Phase 2 and Hitachi structurally unlock capacity; track record of on-time execution
75% of growth is pricing/mix, not volume; vulnerable to commodity deflation
Essentials 11–12% margin is cyclic upside; mid-single-digit baseline likely over cycle
Working capital surge signals precautionary stocking; normalization depends on external stabilization
Specialty +17% YoY lags; ramp under new capacity unproven; margin recovery deferred
No FY27 guidance; Q2 explicitly hedged; management signaling low forward visibility
FII trimming (−45 bps QoQ); institutional caution on commodity tailwinds
Risks, ranked by severity for a holder
Commodity price normalization
HighAcetic acid +200% in March, methanol higher, ethyl acetate spreads at 12-year highs. If these normalize or reverse, margins compress sharply. Essentials 11–12% rolls to mid-single-digit. Q1 margins not repeatable without commodity tailwind.
Working capital normalization and cash headwind
MediumPrecautionary stocking tied up cash in Q1. Normalization depends on commodity and demand stabilization — timeline unclear. Until then, liquidity pressure and higher carrying costs.
Essentials margin cyclicality and earnings quality
MediumQ1 11–12% is upside outlier, not run-rate. Management targets mid-single-digit over cycle. Reversion will disappoint consensus and trigger valuation reset.
Specialty underperformance and ramp execution
MediumSpecialty +17% vs Essentials +50% raises momentum concerns. Dahej Phase 2 and Hitachi ramp are unproven. Margin recovery to 20–25% deferred; timing and quantum uncertain.
Geopolitical supply chain volatility
MediumManagement explicitly hedged Q2 due to West Asia 2.0, Gulf of Hormuz tensions, South China typhoon. Logistics bottlenecks, freight spikes, and vessel scarcity near-term headwinds.
Capex execution and project ROE shortfalls
Low-MediumDahej Phase 2 and Hitachi are ₹125–150 Cr capex. If execution slips or ROE assumptions don't hold, incremental return below cost of capital. Analysts pressed; management deferred specifics.
1 · Q2 volume and margin without commodity tailwind
Does Essentials margin hold above mid-single-digit guidance, or does it revert? Acetic acid, ethyl acetate, methanol pricing trends will be the tell. Commodity normalization = margin compression.
2 · Working capital normalization pace
How quickly does inventory and receivables convert? Is precautionary stocking still elevated, or has it normalized? Cash flow will clarify liquidity risk.
3 · Dahej Phase 2 capex progress and customer qualification
85% capex capitalized Q2, customer qualification target Q3, ramp Q4 FY27. Any slips or cost overruns will push FY28 upside. Execution proof is the bull case.
4 · Specialty revenue momentum and ramp unlock
Does Specialty accelerate as new capacity ramps? Margin recovery toward 20–25% or remains compressed? Management deferred; next call needs quantified guidance.
Laxmi posted a strong quarter on paper — 40% revenue, 217% PAT. But the earnings are borrowed from commodity spikes, not organic gain. Management's caution on margins (11–12% is cyclic upside), deferral of FY27 guidance, and explicit hedging of Q2 all signal that the company sees the quarter as an outlier, not a turn.
The market's 9–10% sell-off and institutional trimming reflect this read. The stock is not cheap at this valuation if margins revert to mid-single-digit baseline. Conversely, Dahej Phase 2 and Hitachi capex, if executed on time, could unlock 15–18% FY28–29 earnings growth, rewarding patient holders.
For now: Hold. The catalyst is Dahej capex completion Q2, customer qualification Q3, and ramp Q4 FY27, paired with Q2 proof that Essentials margins don't collapse without commodity tailwind. The number to track is working capital normalization and Essentials margin trajectory toward mid-single-digit guidance. Guidance risk is high; execution risk is medium.